Results 31 to 40 of about 45,300 (214)

Targeted Therapy of Myelofibrosis [PDF]

Клиническая онкогематология, 2017
Background. Myelofibrosis (primary myelofibrosis, post-essential trombocythemia myelofibrosis, post-polycythemia myelofibrosis) is the most complex and pressing problem among all Ph-negative myeloproliferative diseases. The present article summarizes the
OYu Vinogradova, VA Shuvaev, IS Martynkevich, MM Pankrashkina, MS Fominykh, EV Efremova, KYu Krutikova, LB Polushkina, NN Sharkunov, SV Voloshin, AV Chechetkin   +10 more
doaj   +1 more source

Case Report: Hematologic Recovery Following Stereotactic Ablative Radiotherapy in a Patient With Early-Stage Non-Small Cell Lung Cancer and Paraneoplastic Myelofibrosis

Frontiers in Oncology, 2022
Herein, we report the first case presentation of paraneoplastic myelofibrosis associated with cancer. Paraneoplastic syndromes occur in some patients with thoracic malignancies; however, myelofibrosis is not commonly seen in non-small cell lung cancer ...
Lindsey Sloan, Lindsey Sloan, Rakhi P. Naik, Kavita Umrau, Rena Ruiyu Xian, Kristen A. Marrone, Khinh Ranh Voong   +6 more
doaj   +1 more source

The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells. [PDF]

, 2020
Background:Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs).
Craver, Brianna M, Fleischman, Angela G, Huynh, Christy, Morse, Sarah J, Nguyen, Hellen, Nguyen, Jenny, Nguyen, Thanh Kim   +6 more
core  

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]

, 2016
The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core   +2 more sources

Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up

Haematologica, 2014
Thrombopoietin-receptor agonists increase platelet counts by stimulating the thrombopoietin receptor. Bone marrow fibrosis has been reported in patients receiving thrombopoietin-receptor agonists.
Waleed Ghanima, Julia Turbiner Geyer, Christina S. Lee, Leonardo Boiocchi, Allison A. Imahiyerobo, Attilio Orazi, James B. Bussel   +6 more
doaj   +1 more source

The degree of anisocytosis predicts survival in patients with primary myelofibrosis [PDF]

, 2016
Introduction: Red cell distribution width (RDW) provides a quantitative measure of anisocytosis and it is associated with the presence of subclinical systemic inflammation and a poor outcome in a variety of diseases when elevated.
Hariš, Višnja, Jakšić, Ozren, Kušec, Rajko, Lucijanić, Marko, Mitrović, Zdravko, Pejša, Vlatko, Piršić, Mario, Prka, Željko, Tomasović-Lončarić, Čedna, Vasilj, Tamara, Štoos-Veić, Tajana   +10 more
core   +1 more source

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia

Revista Brasileira de Hematologia e Hemoterapia, 2011
BACKGROUND: The detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. OBJECTIVE: The aim of this study was to detect the following mutations: JAK2 V617F, JAK2 exon
Leonardo Caires dos Santos, Juliana Corrêa da Costa Ribeiro, Neusa Pereira Silva, Janete Cerutti, Maria Regina Regis da Silva, Maria de Lourdes Lopes Ferrari Chauffaille   +5 more
doaj   +1 more source

JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients [PDF]

, 2015
Background : Three subtypes of myeloproliferative neoplasms (MPNs): Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) showed overlapping phenotype.
Faradz, S. M. (Sultana), Saktini, F. (Fanti), Santosa, S. (Santosa)   +2 more
core   +3 more sources

Drug Repositioning of Pegbing® for Essential Thrombocythemia: Insights from PK/PD Modeling and Extrapolation

Clinical Pharmacology &Therapeutics, EarlyView.
Pegbing® (peginterferon alfa‐2b), a pegylated interferon‐alpha, is approved for the treatment of chronic hepatitis B (CHB) and C. One of its adverse effects is platelet (PLT) suppression. It is currently being repurposed for the treatment of essential thrombocythemia (ET), a rare myeloproliferative disorder characterized by abnormally elevated PLT ...
Weizhe Jian, Yalin Yin, Rong Chen, Junsheng Xue, Jianbo Gu, Zhengfang Du, Ruoyi He, Tianyan Zhou   +7 more
wiley   +1 more source

Correlation of cytogenetics and grade of bone marrow fibrosis in primary myelofibrosis [PDF]

Srpski Medicinski Časopis Lekarske Komore
Introduction/Aim: Primary myelofibrosis is a clonal myeloproliferative neoplasm characterized by bone marrow fibrosis and extramedullary hematopoiesis.
Đorđević Vesna, Peruničić-Jovanović Maja, Šefer Dijana, Bižić-Radulović Sandra, Soldatović Ivan, Todorović-Balint Milena   +5 more
doaj   +1 more source